Atara Biotherapeutics Statistics Share Statistics Atara Biotherapeutics has 6.8M
shares outstanding. The number of shares has increased by 19.77%
in one year.
Shares Outstanding 6.8M Shares Change (YoY) 19.77% Shares Change (QoQ) 15.99% Owned by Institutions (%) 14.06% Shares Floating 3.82M Failed to Deliver (FTD) Shares 949 FTD / Avg. Volume 1.59%
Short Selling Information The latest short interest is 268.04K, so 4.5% of the outstanding
shares have been sold short.
Short Interest 268.04K Short % of Shares Out 4.5% Short % of Float 5.7% Short Ratio (days to cover) 7.64
Valuation Ratios The PE ratio is -1.17 and the forward
PE ratio is -23.82.
Atara Biotherapeutics's PEG ratio is
0.01.
PE Ratio -1.17 Forward PE -23.82 PS Ratio 0.77 Forward PS 1.4 PB Ratio -1.02 P/FCF Ratio -1.45 PEG Ratio 0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Atara Biotherapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.48,
with a Debt / Equity ratio of -0.45.
Current Ratio 0.48 Quick Ratio 0.4 Debt / Equity -0.45 Debt / EBITDA -0.58 Debt / FCF -0.64 Interest Coverage -18.08
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $842.75K Profits Per Employee $-558.19K Employee Count 153 Asset Turnover 1.18 Inventory Turnover 1.97
Taxes Income Tax -12K Effective Tax Rate 0.01%
Stock Price Statistics The stock price has increased by 33.85% in the
last 52 weeks. The beta is 0.26, so Atara Biotherapeutics's
price volatility has been higher than the market average.
Beta 0.26 52-Week Price Change 33.85% 50-Day Moving Average 9.52 200-Day Moving Average 9.15 Relative Strength Index (RSI) 54.17 Average Volume (20 Days) 59,833
Income Statement In the last 12 months, Atara Biotherapeutics had revenue of 128.94M
and earned -85.4M
in profits. Earnings per share was -11.41.
Revenue 128.94M Gross Profit 107.93M Operating Income -83.44M Net Income -85.4M EBITDA -75.75M EBIT -80.8M Earnings Per Share (EPS) -11.41
Full Income Statement Balance Sheet The company has 25.03M in cash and 43.83M in
debt, giving a net cash position of -18.8M.
Cash & Cash Equivalents 25.03M Total Debt 43.83M Net Cash -18.8M Retained Earnings -2.05B Total Assets 62.04M Working Capital -20.71M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -68.72M
and capital expenditures -246K, giving a free cash flow of -68.96M.
Operating Cash Flow -68.72M Capital Expenditures -246K Free Cash Flow -68.96M FCF Per Share -9.21
Full Cash Flow Statement Margins Gross margin is 83.71%, with operating and profit margins of -64.71% and -66.23%.
Gross Margin 83.71% Operating Margin -64.71% Pretax Margin -66.24% Profit Margin -66.23% EBITDA Margin -58.75% EBIT Margin -64.71% FCF Margin -53.48%
Dividends & Yields ATRA does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for ATRA is $18,
which is 73.1% higher than the current price. The consensus rating is "Buy".
Price Target $18 Price Target Difference 73.1% Analyst Consensus Buy Analyst Count 4
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 20, 2024. It was a
backward
split with a ratio of 1:25.
Last Split Date Jun 20, 2024 Split Type backward Split Ratio 1:25
Scores Altman Z-Score -42.9 Piotroski F-Score 2
